Category: Vaccine

Page 13«..10..12131415..2030..»

‘Active’ vaccine adjuvant boosts COVID, flu antibodies in mice – Fierce Biotech

July 11, 2024

Compounds called adjuvants are key to making vaccines created from inactive viruses strong enough to generate an immune response. Now, researchers think they may have found one of the most potentadjuvantsyet: an immunomodulating small molecule called PVP-037.

In principle, this compound can be added to any vaccine to enhance its action, Ofer Levy, M.D., Ph.D., a Boston Childrens Hospital scientist and the lead author on a July 3 Science Advances article describing the discovery, said in an accompanyingpress release. PVP-037 is one of the most active adjuvants weve discovered, and we think it induces a greater, more durable, and broader immune response to vaccines.

The researchers identified PVP-037 by screening a 200,000-plus library of small molecules found in human immune cells. Of the 25 hits the analysis returned, PVP-037 was the most active.

The compound is whats known as an imidazopyrimidine, a versatile molecule often used in drug development across a wide range of diseases. Cell studies on donor immune cells showed that PVP-037 activated immune pathways and cytokine production. In mice, an optimized form of the adjuvant boosted antibodies against flu and SARS-CoV-2, the virus that causes COVID-19, when given alongside disease-causing antigens.

Of course, efficacy alone isnt enoughfor an adjuvant to be useful, it needs to be easily integrated into the vaccine development timeline. Here, too, PVP-037 seems to be a good fit. The compound is stable and can be formulated in most drug delivery systems, like oil-in-water emulsions. Its also easy to work with, according to the researchers.

The study is limited by the fact that the experiments were in mice and that the mechanisms by which the adjuvant works werent totally clear. Further, the researchers still need to study how it performs in the presence of actual pathogens, not just key proteins, they wrote in their paper. There are other details to work out as well.

Immunization studies were undertaken at relatively short time points, such that future studies are needed to assess the impact of PVP-037 on durability of immune responses, they wrote in the article. Although we focused on [antibody] responses as important correlates of protection against influenza and SARS-CoV-2 further studies should assess T cell responses along with toxicity studies on stable formulations.

Meanwhile, Boston Childrens and the researchers have already patented the adjuvant and plan to use funds from the National Institute of Allergy and Infectious Diseases to study whether the adjuvant works across age groups. Theyll be looking at its performance inside influenza, whooping cough and opioid vaccines to prevent fentanyl overdose deaths, according to the press release.

The work on imidazopyrimidines as immunomodulatory compounds has been patented, too, and will eventually be studied for applications in allergy and cancer treatments.

Here is the original post:

'Active' vaccine adjuvant boosts COVID, flu antibodies in mice - Fierce Biotech

HilleVax’s norovirus vaccine ineffective in large trial of infants – BioPharma Dive

July 9, 2024

Dive Brief:

According to the Centers for Disease Control and Prevention, norovirus is the leading cause of foodborne illness, vomiting and diarrhea. Outbreaks occur when infected people make direct contact with other individuals. Contact with contaminated food, water and surfaces can also lead to infection.

Norovirus outbreaks commonly occur in healthcare facilities, as well as in schools and childcare centers. Children younger than 5 years, as well as older adults or people who are immunocompromised are at higher risk of severe infection.

HilleVax has sold investors on the promise of its vaccine being first to a market it estimates to be worth multiple billions of dollars. The company prioritized seeking approval in infants first, although it has been considering the adult market as well.

The Phase 2b study, dubbed NEST-IN1, was a randomized, placebo-controlled trial of more than 3,000 healthy infants in the U.S. and Latin America. Results showed that vaccine efficacy against moderate or severe acute gastroenteritis was only 5%, with 25 cases in the vaccine arm and 26 cases in the placebo group.

While HIL-214 previously showed clinical benefit in adults, NEST-IN1 was the first efficacy study conducted in infants for a norovirus vaccine candidate, Rob Hershberg, CEO of HilleVax, said in a statement. We believe the efficacy in the infant setting may have been impacted by the appearance of multiple emerging GII.4 strains in this trial.

The company said HIL-214s safety and immune response profile was consistent with prior testing.

HilleVax was launched in 2021by Takeda Pharmaceuticals and Frazier Healthcare Partners with a license to what was then Takedas norovirus vaccine candidate.

More:

HilleVax's norovirus vaccine ineffective in large trial of infants - BioPharma Dive

MRSA Vaccine Breakthrough: Scientists Find a Promising Way to Fight a Deadly Superbug – SciTechDaily

July 9, 2024

Trinity College Dublin researchers have developed a promising approach to combat MRSA by targeting the immune suppressor IL-10 during vaccine delivery. As MRSA continues to evade traditional antibiotics, this innovative strategy offers new hope for effective vaccines against S. aureus infections, which are major contributors to mortality worldwide.

Researchers have made significant progress in the fight against MRSA by enhancing vaccine efficacy through targeting IL-10, an immune-suppressing molecule. Their findings suggest that neutralizing IL-10 can potentiate the immune response and aid in the clearance of the bacterium in animal models.

Scientists from Trinity College Dublin have taken a leap forward in understanding how we might fight back against the potentially deadly MRSA bacterium. They have shown in an animal model that targeting a key suppressive immune molecule (IL-10) during the delivery of a vaccine improves the ability of the vaccine to protect against infection.

The bacterium Staphylococcus aureus is one of the leading causes of community- and hospital-acquired bacterial infection, and is associated with over one million deaths worldwide each year. Unfortunately, antibiotics are becoming increasingly less effective against this bacterium with the antibiotic-resistant form, MRSA, responsible for the highest number of deaths in high-income countries that are attributable to antimicrobial-resistant bacterial infections.

As a result, scientists are keenly focused on finding solutions to turn the tide in fighting S. aureus-related infections. One hugely appealing option is a vaccine but, while some progress has been made on that front in recent years, a number of major hurdles remain. One of these appears to be the bacteriums ability to dampen the immune response by turning on one of the natural breaks that exists within the immune system, an important immune-suppressive molecule known as Interleukin-10 (IL-10), which acts to reduce inflammation in the body.

Digitally colorized scanning electron microscopic image of Staphylococcus aureus bacteria (mustard-colored) enmeshed within a human white blood cell (red-colored). Credit: NIAID

The interesting thing about S. aureus is that in addition to being a deadly pathogen, forms of this bacteria live in and on our bodies without causing harm. During these asymptomatic interactions the bacterium is, however, shaping the immune response meaning that when a vaccine against S. aureus is administered the immune system struggles to respond appropriately.

Here, in the work published today (July 8) in a leading journal, JCI Insight, the researchers showed in the animal model that if they immunized subjects with a vaccine that primed their immune systems to respond to infection in tandem with antibodies that neutralized IL-10, the immune response (via specialized T cells) was improved and bacterial clearance was likewise improved following subsequent infection.

Staphylococcus aureus is a common bacterium that can be found on the skin and in the noses of many people. While typically harmless, it can cause a range of mild to severe infections if it enters the body through cuts or other wounds. Infections can include skin issues like boils and impetigo, and more serious problems such as pneumonia, bloodstream infections, and endocarditis. A particularly concerning aspect of Staphylococcus aureus is its ability to develop resistance to antibiotics, notably seen in MRSA (Methicillin-resistant Staphylococcus aureus), which is difficult to treat and is known for causing severe hospital-acquired infections.

The research team was led by Rachel McLoughlin, Professor in Immunology in Trinity College Dublins School of Biochemistry and Immunology. Rachel, who is based at the Trinity Biomedical Sciences Institute, said: Taken in combination, our results offer significant promise for what would be a novel strategy for improving the efficacy of vaccines developed with the aim of suppressing S. aureus infection.

Our work also strongly suggests that prior exposures to this bacterium may create a situation whereby our immune system no longer sees it as a threat and thus does not respond appropriately to a vaccine due to the creation of this immune-suppressed state. Again, this underlines why immunization delivered with something that helps neutralize IL-10 offers renewed hope for effective vaccines against S. aureus.

Reference: IL-10 inhibition during immunization improves vaccine-induced protection against Staphylococcus aureus infection by Alanna M. Kelly, Karen N. McCarthy, Tracey J. Claxton, Simon R. Carlile, Eoin C. OBrien, Emilio G. Vozza, Kingston H.G. Mills and Rachel M. McLoughlin, 8 July 2024, JCI Insight. DOI: 10.1172/jci.insight.178216

Funding: Wellcome Trust, Irish Research Council, Science Foundation Ireland

Excerpt from:

MRSA Vaccine Breakthrough: Scientists Find a Promising Way to Fight a Deadly Superbug - SciTechDaily

Richmond doctor shares thoughts on ‘remarkable’ breast cancer vaccine – CBS 6 News Richmond WTVR

July 9, 2024

RICHMOND, Va. -- There's currently no FDA approved vaccine to treat breast cancer patients. However, a national clinical trial is trying to develop a vaccine targeting one of the most aggressive forms of cancers for one breast cancer group in particular.

This vaccine is remarkable, Dr. Masey Ross, an oncologist with VCU Massey Comprehensive Cancer Center, said.

A national clinical trial is looking to develop a vaccine to treat women with metastatic triple negative breast cancer.

So, that means breast cancer that has spread outside the breast and lymph nodes, Dr. Ross said.

Triple negative breast cancer is an aggressive form of cancer. Fifteen percent of breast cancer patients have that type of cancer and the standard of treatment is chemotherapy and immunotherapy.

As triple negative cancer is growing and dividing, it can acquire different mutations with its genetic material, Dr. Ross said.

In the national trial sponsored by the National Cancer Institute, some triple negative breast cancer patients will receive the standard care of treatment. The other women in the trial will receive the vaccine.

The idea behind the trial is to combine the vaccine with immunotherapy and chemotherapy to lead to a longer (life), prevent further growth and spread of the cancer. Help women live longer, better lives. Dr. Ross said.

What makes the vaccine so different is its personalized.

So, each vaccine is made from a specific woman's biopsy from her tumor because each cancer is slightly different, Dr. Ross said.

Once each personalized vaccine is created, it goes to work.

It's a way of training the body's immune system to recognize those cancer cells or tumor cells as foreign so the immune system can go in and then attack the tumor, Dr. Ross said.

If the vaccine shows positive results, it could lead to FDA approval and that process could take years.

EAT IT, VIRGINIA restaurant news and interviews

Here is the original post:

Richmond doctor shares thoughts on 'remarkable' breast cancer vaccine - CBS 6 News Richmond WTVR

Clinic in Chicopee offering free vaccinations for dogs and cats – WWLP.com

July 9, 2024

CHICOPEE, Mass. (WWLP) Second Chance Animal Services is teaming up with Teddy Bear Pools and Spas in Chicopee as part of a free vaccine clinic for dogs and cats.

Free distemper and parvo vaccinations will be available along with rabies vaccinations for $1 and microchipping for $22. The clinic will take place at Teddy Bear Pools and Spas located at 41 East Street in Chicopee on Friday, July 19th from 10 a.m. to 2 p.m.Pre-registrationis recommended however, walk-ins are also welcome based on availability.

Parvo is a highly contagious disease that can be deadly and affects mainly young and unvaccinated dogs.Once infected, the virus attacks a dogs gastrointestinal system. Some signs of parvo typically begin within 7-14 days following exposure include:

Ted Hebert, owner of Teddy Bear Pools said, Barbara and I are humbled to have the opportunity to help our furry friends and the communities we serve.

Lindsay Doray, Chief Development Officer of Second Chance, shared, We are excited to once again partner with Teddy Bear Pools to bring lifesaving vaccines to area pets. This clinic is open to all pet ownersyou dont need to live in Chicopee to register. Doray also extended gratitude to PetcoLove for their generous grant, which makes this clinic possible.

A grant was provided by PetcoLove with all services administered by Second Chance veterinary professionals. Free pet beds donated by Chewy are available while supplies last.

Second Chance Animal Services is a nonprofit animal welfare organization founded in 1999. It has grown from a small, volunteer-run shelter into a community resource that helps over 49,000 animals annually. Low-cost vaccine clinicsare also available weekly in their veterinary hospitals at North Brookfield, Southbridge, Springfield, and Worcester.

For those wishing to donate to the animal shelter, the following supplies are needed:

WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.

Original post:

Clinic in Chicopee offering free vaccinations for dogs and cats - WWLP.com

Merck washes hands of 1,000-plus Zostavax lawsuits – FiercePharma

July 9, 2024

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax.

Late last week, the U.S. Court of Appeals for the Third Circuit tossed an appeal to resurrect certain lawsuits claiming Mercks popular shot caused patients to develop shingles.

The appeals court made its decision after the plaintiffs filed a voluntary dismissal some two years after logging a loss in Pennsylvania, court documents show.

With the appeals court snub, the plaintiffs could conceivably still take their cases to the Supreme Court.

Merck still faces claims from plaintiffs in other states who argue Zostavax caused various other injuries besides shingles plus those contending the vaccine causes hearing loss. As of summer 2021, Merck was facing some 1,950 lawsuits related to Zostavax. The December 2022 ruling against the plaintiffs knocked out 1,189 cases.

At the time, the court determined that the medical expert on deck to prove that Zostavax caused patients shingles failed to consider whether the plaintiffs disease occurred naturally because theyd had chickenpox as kids.

Chickenpox and shingles, also known as herpes zoster, are caused by the varicella-zoster virus. The judge overseeing the December 2022 dismissal pointed out that [v]irtually all persons over the age of 30 in the United States have had chickenpox and carry the so-called wild-type virus in their systems.

He added that Merck provided the court uncontradicted medical authority that a laboratory test of a persons shingles rash was the only way to tell whether the shingles was caused by the virus strain contained in Zostavax or by the wild-virus strain from chickenpox closeted in a persons body.

Merck, for its part, hasnt sold Zostavax in the U.S. since 2020.The shot was once the premier shingles immunization in the states, but it was quickly usurped once GSKs Shingrix hit the scene in 2017.

Earlier in 2022, meanwhile, Merck prevailed in another Zostavax case in Ohio when a federal judge tossed a lawsuit alleging the company misled consumers about the vaccines effectiveness, especially in older adults.

Here is the original post:

Merck washes hands of 1,000-plus Zostavax lawsuits - FiercePharma

Five people who survived measles recount the disease’s horrors – Washington Post – The Washington Post

July 9, 2024

July 7, 2024 at 5:00 a.m.

Lena H. Sun, a Washington Post national health reporter, has been reporting on rising measles outbreaks in the United States in recent years amid falling vaccination rates.

These days, most Americans dont think about measles because vaccination had largely eliminated the scourge from the United States in 2000. Many doctors cannot even diagnose measles because they have not seen it in practice. But measles outbreaks are back. There have been more cases this year than in each of the past two years.

The measles virus is one of the most contagious on Earth; it can live for up to two hours in the air after an infected person coughs or sneezes. Up to 9 out of 10 people who are not protected will become infected if they breathe the contaminated air or touch a surface that has been infected. Measles is especially deadly for babies and young children who are not vaccinated.

The WHO declared measles eliminated in the U.S. in 2000

In 2014 and 2019, localized outbreaks caused a spike in cases

Reports of measles dropped during covid-19

*Data through June 27, 2024

Source: Centers for Disease Control and Prevention

In the decade before a vaccine became available in 1963, more than 3 million people contracted measles every year in the United States; 48,000 were hospitalized, and about 400 to 500 died (many of them children), according to the Centers for Disease Control and Prevention.

Many people who survived measles as children before a vaccine existed never forgot how sick they were. They wanted to share their stories so others could understand what it was like to have measles and its long-term consequences.

They remember being confined in dark rooms to lessen the risk of blindness, a serious complication. They remember classmates and family members who died of other severe complications, such as dehydration or pneumonia, or swelling of the brain.

Here are their memories of surviving measles, in their words, edited for clarity:

Story continues below advertisement

Wilde, a retired teacher for the visually impaired, was in second grade in 1963. The measles vaccine was already available, but she remembers her mother telling her years later that it was not yet in widespread use.

I just remember being very sick. I remember lying on the couch in the living room and being very hot, like I was under the sun. My parents were arguing about what to do. They seemed to be millions of miles away. I felt very detached. My fever was very, very high, and I was not responding to them when they were speaking to me.

They were afraid to call an ambulance because they werent sure if I was well enough to be taken to the hospital. They called the pediatrician. The next thing I remember, he was patting my face and I could see his nose hairs and feel his breath. He was calling my name and trying to rouse me. He said, Weve got to bring the fever down, and told my mother to run cold water in the bathtub. He was concerned about brain swelling.

They stripped me down, wrapped me in a cotton sheet and put me in the bathtub. I remember I felt like I was screaming with every bit of strength in my body.

My mother told me later, You sounded like a dying kitten.

I was in the back bedroom in the dark for several weeks to protect my vision. Gradually I got better. But I remember my eyes aching and me squinting. There are a lot of photos of me holding up a hand to shield my eyes.

Even now, when I get outside, my eyes ache. I also see little sparkles of light when I am in the dark. I know that is part of aging, but I still suspect if I had not had a severe bout of measles, I would have come through with far fewer vision problems.

McGregor-Foxcroft, a retired fingerprint technician, was in first grade in 1956. The measles vaccine was not yet available. Her older siblings had already had measles, as did many of her classmates.

I was 5 or 6. I had to be confined to a dark room, which was pure torture because I was just so bored. I couldnt join the family for dinner. I couldnt watch TV or any of that stuff. I couldnt read.

I did something very naughty. I wrote a note on a piece of paper. It said, Help, Im being held prisoner. And I pitched it out my bedroom window. And a neighbor showed it to my mother. And she just about had kittens.

She handed it to my dad and said, The poor child is going crazy.

Another week after that, I was allowed to read or write for an hour in the morning and an hour in the afternoon.

When I went back to school, I didnt have the energy to walk home for lunch. It was probably three-quarters of a mile. Sometimes the neighbor would just drive me home. They knew how tired I got.

Tim, a software engineer, spoke to The Washington Post on the condition that only his middle name be used because his family has been harassed for not vaccinating him as a child. He became infected as an adult in 2016 after attending a crowded school event and was hospitalized.

I attended a family members school ceremony in a large auditorium. That same evening, I flew out to Las Vegas for a conference. About three or four days after I got home, I started to get sick.

I had a fever up to about 104. And I started to get this terrible headache that felt like the worst flu I had ever had combined with the worst hangover that I had ever had. A day or two after, I got out of bed to use the bathroom and I just collapsed in the hallway.

My partner drove me to an urgent care facility. They tested me for strep throat. They ruled out meningitis. They didnt get a positive diagnosis of strep. But they prescribed me some antibiotics and sent me home. I took the antibiotics for a couple of days, but I just kept getting worse. And I woke up one morning and my body was just covered in red spots.

Story continues below advertisement

I ended up going back to the ER. Somebody asked me if Ive been vaccinated against measles. This is when I realized that I wasnt actually sure. I got confirmation from my mom that I had not been. They ran more tests and confirmed that I did, in fact, have measles.

They admitted me to the hospital into an isolation room. It was a teaching hospital, and it was the most surreal experience because no one had seen measles before.

They would bring in an army of doctors, and I had people asking, Can I take a picture with you?

I start getting calls from our health department. They want to track down what happened. It turns out, at the graduation I went to, someone flew in from out of the country and had measles. I must have somehow walked past them. I didnt interact with anyone. I didnt shake anyones hands. I didnt have any conversations with anyone that was not my family. A little bit of errant air coming my way that was all it took.

I was in the hospital three or four days. They sent me home under pretty strict guidelines not to go anywhere. This kind of started a whole new chapter of challenges. I lost about 20 to 25 pounds in the process. Walking upstairs, I would just be completely winded.

I ended up with immune amnesia, where it basically resets the bodys immune system. Everything that I would get exposed to I would get sick. And every time I would get sick, I would get the worst version of being sick. Like, one of the bad colds I got turned into this full-on bronchitis where I just had no ability to talk. It totally changed the trajectory of my life for more than half a year.

I was recently diagnosed with an autoimmune disease, and I dont necessarily know that its linked to measles. But Ive kind of come to look at all of these things, at least in some way, as connected.

Tidwell, a retired attorney for the U.S. Postal Service, got sick as a kindergartner in 1961, before the first vaccine was available. He infected his pregnant mother, who passed it on to his baby sister.

My father was in the U.S. Army. We lived on an Army base in Wertheim, Germany. Everyone in my kindergarten class had measles. I got measles. I had bumps; I had the itching. As a young boy, you almost wanted whatever was going around. You didnt think of it as potentially deadly. It was sort of a badge of honor.

My mother got them from me during the course of her pregnancy.

After my sister Dianna was born in March 1962, early tests showed she had some sort of visual problems. Doctors tried to correct them with surgery. The surgery got botched. Then, at some point, it became evident she was going to be developmentally challenged.

My father was transferred to Fort Sam, Tex., and thats when [my sister] experienced her first epileptic seizure. Over time, she began to develop a swallowing disorder. She lived with the family for as long as my parents were able to take care of her. Then, over time, she began to lose motor control; she lost the ability to walk. She had recurring bouts of pneumonia, and recovery always left her at a lower plateau.

She died in October 1995. She was 33.

Dianna was the glue of our family. She never stopped believing in Santa Claus, which allowed the rest of us to take joy in playing along for a lot longer than most families get a chance to. Though she could never read, Dianna knew that the stories she liked were in books, and she liked making us read to her. Sometimes, shed hand me two socks and insist on a puppet show. Nothing cracked her up more than when two puppets got into a fight. Keeping Dianna amused bonded us and taught me a lot about improvisation and flexibility that would serve me well throughout my life.

Leonhard, a retired teacher of English as a second language, was 6 in 1958. The first vaccine was not yet available. She was in a coma and unable to walk for a period.

I was 6 years old when I got measles. It was 1958. That summer my brother and sister and I got it. I remember being feverish and feeling miserable. I remember my mom sending me upstairs to get something off the dresser. I ran upstairs and all of a sudden my legs gave out and I couldnt walk. I couldnt move my arms. I remember it was too hard to carry me up and down the stairs, so they finally made a bed for me in the living room on the couch. My mom made a tent of blankets and put me in there and had me breathe steam and spit out phlegm because I guess they were concerned about pneumonia starting.

Story continues below advertisement

One night, I remember being swept up and taken to the hospital. I went into a coma on the way there. The last thing I remember was getting in the car. Everything went black. We went to the same hospital where my grandfather was dying. I thought when my parents put me in the car I was going to see Granddaddy. I remember talking to him. I remember saying to the people standing around the bed, I want to go with him. And they said, No, you cant go with him. You need to go back to your room. The next memory I have I woke up from the coma.

That was like seconds to me, but I was in a coma for 30 days. I could talk, but I couldnt walk. The doctor was saying, Say, The bear went over the mountain. And I said it.

And he said, Shes okay. But shell never walk again.

But I taught myself how to walk. While my parents were gone to close up the family home, I remember pulling myself from one piece of furniture to another, dragging my body and just willing myself to walk. I didnt want to be in that wheelchair. When they came home, I ran up to them, Look, I can walk!

Mom told me that before I had encephalitis [a complication from measles], I could hear a story once and repeat it word for word. After that, I had a hard time learning. I had problems focusing in school. I lost my confidence. It was hard to learn and hard to relate to people. I worked really hard, graduated high school with honors. I have a masters in English literature.

But Im going to be seeing a neurologist because Im experiencing some nerve things. I dont know if its related to encephalitis.

Story continues below advertisement

Read this article:

Five people who survived measles recount the disease's horrors - Washington Post - The Washington Post

Tulsa Health Department now allowing walk-ins for back-to-school vaccine updates – KOKI FOX 23 TULSA

July 9, 2024

TULSA, Okla. Tulsa Health Department (THD) wants you to avoid the back-to-school rush to update your childs vaccines.

Appointments wont be necessary this year to update your childs vaccines at THD since theyre now allowing walk-ins.

We want our students to be ready for back to school, said J.P. Williams, associate director of preventive health services at THD.

We want to provide as many opportunities for parents as far as our locations, Williams said.

Williams said THD is making it more convenient for families to beat the rush.

Every Tuesday and Thursday in July, the location at 3rd & Utica and the location at 5635 N. M.L.K. Jr. Blvd will be open for walk-ins.

THD has four locations, which can be viewed by clicking here.

The James O. Goodwin Health Centers public health clinic at 51st Street & 129th East Ave is temporarily closed for remodel.

We also have the caring van so if you cant make it to any of our clinic sites, look for that caring van throughout the community, Williams said.

THD will also offer shot records and birth certificates to help families with everything they need to enroll in school.

According to THD, in Oklahoma, all children must present an immunization record or file an exemption before they can attend public school.

THD gives vaccines at no charge to kids up to age 18.

We want parents to avoid the rush, start now, so you can enjoy the rest of your summer vacation, Williams said.

See original here:

Tulsa Health Department now allowing walk-ins for back-to-school vaccine updates - KOKI FOX 23 TULSA

SNHD offering vaccinations ahead of the new school year – KTNV 13 Action News Las Vegas

July 9, 2024

CLARK COUNTY, Nev. (KTNV) While the calendar may say July, it's not too early to start thinking about back to school.

The new school year begins August 12 and the Southern Nevada Health District is advising parents to make an appointment now for back to school vaccinations.

The Clark County School District requires a number of vaccinations for students enrolling in school.

For a complete list of CCSD vaccination requirementsas well as immunization clinic locations by appointment onlysee the information and links below.

CCSD: Student Enrollment Process

All vaccinations are by appointment only.

Southern Nevada Health District Main Facility

East Las Vegas Public Health Center

Henderson Public Health Center

Mesquite Public Health Center

Back-to-School vaccinations for ages 11-18 years old available at these locations:

Boulevard Mall (in El Mercado)

Fremont Public Health Center

Back-to-School vaccinations on first come, first serve basis at this location:

CCSD Family Support Center

For more information, visit the SNHD website by clicking the link here: Back to School Vaccine Clinics

Read the rest here:

SNHD offering vaccinations ahead of the new school year - KTNV 13 Action News Las Vegas

Maternal RSV Vaccine Appears Safe, Real-World Study Finds – Medpage Today

July 9, 2024

Administration of the maternal respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo) didn't come with an increased risk of preterm birth or other negative neonatal outcomes, according to a retrospective study.

Preterm birth, before 37 weeks' gestation, was actually numerically less common for women who received Pfizer's maternal RSV vaccine than without it (5.9% vs 6.7%, adjusted OR 0.87, 95% CI 0.62-1.20), Moeun Son, MD, of Weill Cornell Medical College in New York City, and colleagues reported in JAMA Network Open.

No significant differences emerged by vaccination status in small-for-gestational-age birthweight, stillbirth, neonatal ICU admissions, respiratory distress with NICU admissions, or neonatal jaundice, hypoglycemia, or sepsis. Percentages of spontaneous and nonspontaneous premature births were similar as well.

"Patients and clinicians can feel confident that the vaccination during pregnancy is a safe way to protect infants from harmful RSV infections," Son told MedPage Today in an email.

"The data are particularly reassuring," she added, "because we include a broader group of women, including some with health conditions that could increase the risks of poor pregnancy outcomes who were excluded" from the MATISSE study, the phase III clinical trial that led to the vaccine's approval.

However, in a time-dependent model, researchers did find an association of the vaccine with hypertensive disorders of pregnancy. Among women who received the vaccine, 20.1% were diagnosed with a hypertensive disorder during pregnancy versus 18.1% of the group that received no vaccine (HR 1.43, 95% CI 1.16-1.77).

This initial postmarketing study suggests "the benefits of the vaccine greatly outweigh the risks," Annette Regan, PhD, MPH, of the University of San Francisco's School of Nursing and Health Professions, wrote in an accompanying editorial.

"While these data provide initial reassurance that the vaccine was not associated with preterm birth in this setting, there are important limitations to consider, and some findings warrant further investigation," Regan cautioned. "Results were not stratified by onset of labor, making it difficult to disentangle whether preterm birth with a spontaneous onset may differ by vaccination status," she noted.

Before Pfizer's vaccine received FDA approval in August 2023, phase III clinical trial data raised concerns about a 1% higher rate of preterm birth observed in women who had received the vaccine compared with women in the control group. Women in those trials received the vaccine from weeks 24 through 36 of pregnancy. Given this potential risk, the FDA limited approval for Pfizer's vaccine to use during gestational weeks 32 through 36.

Of note, GSK recently decided to halt a phase III clinical trial of a similar RSVpreF vaccine because of a 1.9% absolute higher rate of preterm birth observed in the intervention arm. In that trial, women randomized to the vaccine arm received it between 24 and 34 weeks of gestation.

Regan also speculated that the real-world study drew from a population that is healthier than the general U.S. birthing population, given that the 6-7% preterm birth rate observed in this cohort is lower than the national preterm birth rate of 10-11%. "Replication in larger and more diverse cohorts of US pregnancies would therefore be helpful," she wrote.

The retrospective observational cohort study looked at data from 2,973 pregnant women from two New York City hospitals within one healthcare system who gave birth at 32 weeks of gestation or later from September 2023 through January 2024. Of these, 34.5% had received the prenatal RSV vaccine. The median age was about 35 years.

The maternal RSV vaccination rate at the hospitals was almost double that of the nationally reported rate of 17.8% during the study period, Son noted.

Researchers found some disparities in vaccination rates, she said. Black women, women with public insurance, and those who had fewer prenatal visits were less likely to be vaccinated. These disparities are similar to those previously seen for other recommended vaccines during pregnancy, she pointed out.

"As we prepare for the next RSV vaccination season, which starts this September, we are going to speak with different communities to help understand what might cause vaccine hesitancy among women or create barriers to access the vaccine, so we can improve vaccination rates even more this year," Son told MedPage Today.

Katherine Kahn is a staff writer at MedPage Today, covering the infectious diseases beat. She has been a medical writer for over 15 years.

Disclosures

The study was funded by NewYork-Presbyterian Hospital and Weill Cornell Medical College.

Son reported no conflicts of interest, but two co-authors reported ties to Pfizer.

Regan served on the data safety monitoring board for the Moderna mRNA-1345 candidate RSV vaccine.

Primary Source

JAMA Network Open

Source Reference: Son M, et al "Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes" JAMA Netw Open 2024; DOI: 10.1001/jamanetworkopen.2024.19268.

Secondary Source

JAMA Network Open

Source Reference: Regan AK "Perinatal outcomes after RSV vaccination during pregnancy -- addressing emerging concerns" JAMA Netw Open 2024; DOI: 10.1001/jamanetworkopen.2024.19229.

View original post here:

Maternal RSV Vaccine Appears Safe, Real-World Study Finds - Medpage Today

Page 13«..10..12131415..2030..»